微针贴片递送乙型肝炎疫苗:小鼠与恒河猴的免疫原性
研究开发了递送无佐剂单价乙型肝炎表面抗原的溶解性微针贴片,比较其与肌内注射标准疫苗在小鼠和恒河猴中的免疫原性;微针贴片在所有剂量均诱导保护性抗体水平,抗体应答高于无佐剂肌注但低于铝佐剂肌注,且室温6个月保持效价。
要点
- 微针贴片递送5、10、20微克乙型肝炎表面抗原在小鼠和恒河猴均诱导保护性抗体水平(≥10毫国际单位/毫升)。
- 微针贴片诱导的抗乙型肝炎表面抗体应答高于10微克无佐剂肌注疫苗,但低于10微克铝佐剂肌注疫苗。
- 微针贴片在室温20摄氏度至25摄氏度下稳定6个月,保持67±6%的乙型肝炎表面抗原效价。
核心结论
- 微针贴片递送10微克无佐剂单价乙型肝炎疫苗(出生剂量)在小鼠和恒河猴中诱导保护性抗体应答。
- 本研究开发的微针贴片可用于提高资源有限地区的乙型肝炎出生剂量疫苗接种覆盖率,以实现和维持乙型肝炎消除。
研究设计与样本
- 研究开发了递送无佐剂单价乙型肝炎表面抗原的溶解性微针贴片,剂量为5微克、10微克和20微克。
- 比较对象为10微克标准单价乙型肝炎表面抗原经肌内注射,分别以无佐剂单价疫苗或铝佐剂疫苗形式给药。
- 免疫程序:小鼠为0、3、9周三剂;恒河猴为0、4、24周三剂。
主要发现
- 微针贴片递送5、10、20微克乙型肝炎表面抗原在小鼠和恒河猴中均诱导保护性抗乙型肝炎表面抗体水平(≥10毫国际单位/毫升)。
- 在小鼠和恒河猴中,微针贴片递送乙型肝炎表面抗原诱导的抗乙型肝炎表面抗体应答高于10微克肌内注射无佐剂单价疫苗,但低于10微克肌内注射铝佐剂疫苗。
- 所有疫苗组均检测到乙型肝炎表面抗原特异性CD4+和CD8+ T细胞应答。
- 所有组中组织应激、T细胞受体信号和NFκB信号通路均被激活。
- 微针贴片在室温20摄氏度至25摄氏度下稳定6个月,保持67±6%的乙型肝炎表面抗原效价。
临床怎么用
- 作者认为,本研究开发的微针贴片可用于提高资源有限地区的乙型肝炎出生剂量疫苗接种覆盖率,以实现和维持乙型肝炎消除。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination against hepatitis B using a dissolving microneedle patch (dMNP) could increase access to the birth dose by reducing expertise needed for vaccine administration, refrigerated storage, and safe disposal of biohazardous sharps waste. In this study, we developed a dMNP to administer hepatitis B surface antigen (HBsAg) adjuvant-free monovalent vaccine (AFV) at doses of 5 µg, 10 µg, and 20 µg, and compared its immunogenicity to vaccination with 10 µg of standard monovalent HBsAg delivered by intramuscular (IM) injection either in an AFV format or as aluminum-adjuvanted vaccine (AAV). Vaccination was performed on a three dose schedule of 0, 3, and 9 weeks in mice and 0, 4, and 24 weeks in rhesus macaques. Vaccination by dMNP induced protective levels of anti-HBs antibody responses (≥10 mIU/ml) in mice and rhesus macaques at all three HBsAg doses studied. HBsAg delivered by dMNP induced higher anti-HBsAg antibody (anti-HBs) responses than the 10 µg IM AFV, but lower responses than 10 µg IM AAV, in mice and rhesus macaques. HBsAg-specific CD4+ and CD8+ T cell responses were detected in all vaccine groups. Furthermore, we analyzed differential gene expression profiles related to each vaccine delivery group and found that tissue stress, T cell receptor signaling, and NFκB signaling pathways were activated in all groups. These results suggest that HBsAg delivered by dMNP, IM AFV, and IM AAV have similar signaling pathways to induce innate and adaptive immune responses. We further demonstrated that dMNP was stable at room temperature (20 °C-25 °C) for 6 months, maintaining 67 ± 6 % HBsAg potency. This study provides evidence that delivery of 10 µg (birth dose) AFV by dMNP induced protective levels of antibody responses in mice and rhesus macaques. The dMNPs developed in this study could be used to improve hepatitis B birth dose vaccination coverage levels in resource limited regions to achieve and maintain hepatitis B elimination.
引用
- Choi Y, Lee GS, Li S, et al. Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques. Vaccine. 2023. PMID: 37179166. doi:10.1016/j.vaccine.2023.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。